Long Chen1, Kai Hu2, Cheng Cheng1, Quanman Hu1, Liang Zhang1, Tongyan An1, Yongjun Guo2, Shuaiyin Chen3, Guangcai Duan1. 1. Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China. 2. Henan Academy of Medical Sciences, Zhengzhou, Henan, 450046, China. 3. Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China. sychen@zzu.edu.cn.
Abstract
BACKGROUND: Between people with and without inflammatory bowel disease (IBD), there was no statistically significant difference in the probability of contracting the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, the risk of adverse outcomes in IBD patients after virus infection remains unclear. METHODS: Eligible studies conducted from January 1, 2020 to March 17, 2022 were obtained by searching PubMed, Embase, and Web of Science. Information was collected in tables from the included studies. Random-effects and fixed-effects models were used as measures for the pooled estimates. All data were estimated by R version 4.1.3. RESULTS: Twenty-four studies were included. The risk ratio (RR) of adverse outcomes in COVID-19 patients with IBD increased by 32% (RR 1.32; 95% CI 1.06-1.66) relative to COVID-19 patients without IBD. The RR of mortality was higher in COVID-19 patients with IBD from Europe (RR 1.72; 95% CI 1.11-2.67) than in those that were not from Europe (RR 1.00; 95% CI 0.79-1.26; χ2 = 4.67; P = 0.03). Patients with ulcerative colitis were at higher risk of adverse outcomes after SARS-CoV-2 infection than patients with Crohn's disease patients (RR1.38; 95% CI 1.27-1.50). The IBD drugs treatment was associated with the risk of adverse outcomes, the pooled odds ratio (OR) of mesalazine (1.79; 95% CI 1.59-2.02), immunomodulators (1.30; 95% CI 1.10-1.53), and anti-TNF (0.47; 95% CI 0.41-0.53) were assessed. CONCLUSION: COVID-19 patients with IBD had an increased risk of adverse outcomes than those without IBD, whereas anti-TNF treatment might reduce the risk.
BACKGROUND: Between people with and without inflammatory bowel disease (IBD), there was no statistically significant difference in the probability of contracting the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, the risk of adverse outcomes in IBD patients after virus infection remains unclear. METHODS: Eligible studies conducted from January 1, 2020 to March 17, 2022 were obtained by searching PubMed, Embase, and Web of Science. Information was collected in tables from the included studies. Random-effects and fixed-effects models were used as measures for the pooled estimates. All data were estimated by R version 4.1.3. RESULTS: Twenty-four studies were included. The risk ratio (RR) of adverse outcomes in COVID-19 patients with IBD increased by 32% (RR 1.32; 95% CI 1.06-1.66) relative to COVID-19 patients without IBD. The RR of mortality was higher in COVID-19 patients with IBD from Europe (RR 1.72; 95% CI 1.11-2.67) than in those that were not from Europe (RR 1.00; 95% CI 0.79-1.26; χ2 = 4.67; P = 0.03). Patients with ulcerative colitis were at higher risk of adverse outcomes after SARS-CoV-2 infection than patients with Crohn's disease patients (RR1.38; 95% CI 1.27-1.50). The IBD drugs treatment was associated with the risk of adverse outcomes, the pooled odds ratio (OR) of mesalazine (1.79; 95% CI 1.59-2.02), immunomodulators (1.30; 95% CI 1.10-1.53), and anti-TNF (0.47; 95% CI 0.41-0.53) were assessed. CONCLUSION: COVID-19 patients with IBD had an increased risk of adverse outcomes than those without IBD, whereas anti-TNF treatment might reduce the risk.
Authors: Benjamin Rader; Samuel V Scarpino; Anjalika Nande; Alison L Hill; Ben Adlam; Robert C Reiner; David M Pigott; Bernardo Gutierrez; Alexander E Zarebski; Munik Shrestha; John S Brownstein; Marcia C Castro; Christopher Dye; Huaiyu Tian; Oliver G Pybus; Moritz U G Kraemer Journal: Nat Med Date: 2020-10-05 Impact factor: 53.440
Authors: Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann Journal: Cell Date: 2020-03-05 Impact factor: 41.582
Authors: Mayte Suárez-Fariñas; Minami Tokuyama; Gabrielle Wei; Ruiqi Huang; Alexandra Livanos; Divya Jha; Anais Levescot; Haritz Irizar; Roman Kosoy; Sascha Cording; Wenhui Wang; Bojan Losic; Ryan Ungaro; Antonio Di'Narzo; Gustavo Martinez-Delgado; Maria Suprun; Michael J Corley; Aleksandar Stojmirovic; Sander M Houten; Lauren Peters; Mark Curran; Carrie Brodmerkel; Jacqueline Perrigoue; Joshua R Friedman; Ke Hao; Eric E Schadt; Jun Zhu; Huaibin M Ko; Judy Cho; Marla C Dubinsky; Bruce E Sands; Lishomwa Ndhlovu; Nadine Cerf-Bensusan; Andrew Kasarskis; Jean Frederic Colombel; Noam Harpaz; Carmen Argmann; Saurabh Mehandru Journal: Gastroenterology Date: 2020-09-25 Impact factor: 22.682
Authors: Takahiko Toyonaga; Kenza C Araba; Meaghan M Kennedy; Benjamin P Keith; Elisabeth A Wolber; Caroline Beasley; Erin C Steinbach; Matthew R Schaner; Animesh Jain; Millie D Long; Edward L Barnes; Hans H Herfarth; Kim L Isaacs; Jonathan J Hansen; Muneera R Kapadia; José Gaston Guillem; Ajay S Gulati; Praveen Sethupathy; Terrence S Furey; Camille Ehre; Shehzad Z Sheikh Journal: Sci Rep Date: 2021-06-29 Impact factor: 4.379